

CITATION REPORT

List of articles citing

Hydroxychloroquine: the cornerstone of lupus therapy

DOI: 10.1177/0961203307086643

Lupus, 2008, 17, 271-3.

Source: <https://exaly.com/paper-pdf/44807323/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
61	[The antiphospholipid syndrome in the 21st century]. <i>Medicina Clínica</i> , 2009 , 133, 390-6	1	2
60	Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010 , 62, 386-92	4.7	29
59	Treatment of so-called idiopathic follicular mucinosis with hydroxychloroquine. <i>British Journal of Dermatology</i> , 2010 , 163, 420-3	4	17
58	A new role for antimalarials in systemic lupus erythematosus treatment. <i>International Journal of Clinical Rheumatology</i> , 2010 , 5, 299-312	1.5	1
57	Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases. <i>Scandinavian Journal of Gastroenterology</i> , 2011 , 46, 732-7	2.4	36
56	Cutaneous lupus erythematosus: update of therapeutic options part I. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, e179-93	4.5	120
55	Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus. <i>Rheumatology</i> , 2012 , 51, 663-9	3.9	15
54	Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. <i>Lupus</i> , 2012 , 21, 1178-82	2.6	87
53	Antipalúdicos de síntesis en dermatología. <i>EMC - Dermatología</i> , 2013 , 47, 1-8	0.1	
52	Multifaceted effects of hydroxychloroquine in human disease. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 43, 264-72	5.3	88
51	Temporal trends in characteristics and outcome of intensive care unit patients with systemic lupus erythematosus in Taiwan: a national population-based study. <i>Lupus</i> , 2013 , 22, 644-52	2.6	13
50	Belimumab for systemic lupus erythematosus: a practice-based view. <i>Lupus</i> , 2013 , 22, 372-80	2.6	16
49	Antipaludéens de synthèse en dermatologie. <i>EMC - Dermatologie</i> , 2013 , 8, 1-7		
48	Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. <i>Clinical Rheumatology</i> , 2014 , 33, 649-57	3.9	23
47	Recent advances in the treatment of systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2014 , 9, 89-100	1.5	
46	Hydroxychloroquine: a multifaceted treatment in lupus. <i>Presse Medicale</i> , 2014 , 43, e167-80	2.2	101
45	Systemic lupus erythematosus. <i>Lancet, The</i> , 2014 , 384, 1878-1888	40	439

44	The Diagnosis and Treatment of Systemic Lupus Erythematosus. <i>Deutsches Arzteblatt International</i> , 2015 , 112, 423-32	2.5	81
43	Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature. <i>Pediatric Rheumatology</i> , 2015 , 13, 1	3.5	42
42	Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. <i>Inflammopharmacology</i> , 2015 , 23, 231-69	5.1	300
41	Systemic lupus erythematosus: review of synthetic drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2793-806	4	14
40	[Hydroxychloroquine for autoimmune diseases]. <i>Revista Medica De Chile</i> , 2016 , 144, 232-40	0.5	13
39	The skin in autoimmune diseases-Unmet needs. <i>Autoimmunity Reviews</i> , 2016 , 15, 948-54	13.6	8
38	New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1805-9	9.5	2
37	Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 835-48	3.8	56
36	[Cutaneous panniculitis]. <i>Revue De Medecine Interne</i> , 2016 , 37, 743-750	0.1	8
35	Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care. <i>Lupus</i> , 2016 , 25, 838-49	2.6	29
34	[Cardiovascular disease and systemic inflammatory diseases]. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2016 , 28, 94-101	1.4	1
33	[Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus]. <i>Zeitschrift Fur Rheumatologie</i> , 2017 , 76, 27-32	1.9	0
32	Traitement des l3sions cutan3es du lupus 3rythmateux dissimil3Actualites Pharmaceutiques, 2017 , 56, 26-29	0	
31	Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 873-882	5.6	5
30	S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 389-404	4.6	75
29	Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. <i>Lupus</i> , 2017 , 26, 186-194	2.6	23
28	Hydroxycloquine blood concentration in lupus nephritis: a determinant of disease outcome?. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1604-1610	4.3	18
27	Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). <i>Rheumatology</i> , 2018 , 57, 337-344	3.9	56

26	Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016. <i>Clinical Rheumatology</i> , 2018 , 37, 1853-1859	3.9	6
25	Differences in the diagnosis and management of systemic lupus erythematosus by primary care and specialist providers in the American Indian/Alaska Native population. <i>Lupus</i> , 2018 , 27, 1169-1176	2.6	6
24	Hydroxychloroquine affects bone resorption both in vitro and in vivo. <i>Journal of Cellular Physiology</i> , 2018 , 233, 1424-1433	7	17
23	Comment on: Hydroxychloroquine-induced retinal toxicity in an asymptomatic patient. <i>Rheumatology</i> , 2018 , 57, 1689-1690	3.9	
22	Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. <i>Mediators of Inflammation</i> , 2018 , 2018, 3424136	4.3	35
21	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. <i>Arthritis Research and Therapy</i> , 2018 , 20, 133	5.7	26
20	Should Generalized Immunosuppression or Targeted Organ Treatment be the Best Principle for Overall Management of Systemic Lupus Erythematosus?. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 369-377	2.4	
19	Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. <i>Lupus</i> , 2019 , 28, 555-559	2.6	10
18	Update on antimalarials and systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 572-582	5.3	6
17	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. <i>Rheumatology</i> , 2020 , 59, v69-v81	3.9	16
16	B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. <i>Frontiers in Medicine</i> , 2020 , 7, 316	4.9	21
15	Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now?. <i>Lupus</i> , 2020 , 29, 671-675	2.6	1
14	Mechanistic Paradigms of Natural Plant Metabolites as Remedial Candidates for Systemic Lupus Erythromatosus. <i>Cells</i> , 2020 , 9,	7.9	3
13	Hydroxychloroquine: Pharmacological, physicochemical aspects and activity enhancement through experimental formulations. <i>Journal of Drug Delivery Science and Technology</i> , 2021 , 63, 102512	4.5	0
12	Novel Therapeutic Interventions in Systemic Lupus Erythematosus.		
11	Studies on Activities and Chemical Characterization of Medicinal Plants in Search for New Antimalarials: A Ten Year Review on Ethnopharmacology. <i>Frontiers in Pharmacology</i> , 2021 , 12, 734263	5.6	3
10	Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection. <i>Frontiers of Medicine</i> , 2021 , 15, 404-415	12	4
9	Systemic Lupus Erythematosus. 2017 ,		

8	Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2013 , 6, 27-38	1.2	13
7	Hydroxychloroquine versus tacrolimus for the treatment of persistently active systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2021 ,	3.3	0
6	RetINal Toxicity And HydroxyChloroquine Therapy (INTACT): protocol for a prospective population-based cohort study.. <i>BMJ Open</i> , 2022 , 12, e053852	3	
5	How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
4	Thalidomide and discoid lupus erythematosus: case series and review of literature.. <i>Drugs in Context</i> , 2022 , 11,	5.2	0
3	Prednisone and long-term damage in systemic lupus erythematosus: Which is the threshold dose? A pilot study.. <i>Lupus</i> , 2022 , 9612033221093485	2.6	0
2	Systemic lupus erythematosus: overview, management and COVID-19.. <i>British Journal of Nursing</i> , 2022 , 31, 348-355	0.7	
1	Association between cumulative dose of hydroxychloroquine and electrocardiographic abnormalities in patients with systemic lupus erythematosus. 2023 ,		0